U.S. Markets closed

GlaxoSmithKline plc (GSK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
42.66-0.11 (-0.26%)
At close: 4:02PM EDT
People also watch
AZNNVSSNYLLYBMY
  • Cup and handle on today's minute chart. I believe the bottom is in. Hold on tight.
  • Do you have to pay foreign tax on the dividends?
  • As usual Yahoo is unreliable. Bought twice in the 50's, yet historical chart shows all time highs around $47. More Fake News!!
  • Why the drop in GSK over the past two weeks? Market expect poor results?
  • Market up 140.00 and GSK down .21 cents go figure.
  • So, what's the big pullback all about?? Most pharma stocks up today, but GSK loses nearly 1%. After hours market has them trending down nearly 2% for Wednesday's trading. Will this stock EVER break out and test $50 a share?
  • Gsk won, teva loss, but Gsk down after hours?
  • (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • The last time GSK did something like this it blew up. Im not sure about you guys but awe.some.stocks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • Do you think this thing is done selling? Showing us a buy signal now on GSK? Ive been struggling with this stock lately. Some of my other trades have been from awesomeSTO-CKS which are working out pretty well.
  • Mylan just reported they have major amendments needed to their generic Advair application which will delay an FDA response for at least 10 months. Great news for GSK.
  • Does anyone know why GSK still has an R&D division?
  • Charles A. Henriques (Global Popularity Increasing @ Linkedin.com )
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration

    San Francisco Bay Area: Linkedin 1794 Connections

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen
  • Animus is est valde maximus. Quasi viribus roboratur usu. http://dataunion.tistory.com/6978

    MAY-2016 GlaxoSmithKline plc NYSE : GSK Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.1 In other words, the correlation coefficient of the other stocks
    dataunion.tistory.com
  • Been collecting dividends for years. Also a very fat special dividend. I could be happy if the price stays in the low 40's for the next 3 decades. I will sell when the bank's start paying 6 percent interest. Wake me up when that happens.
  • Earnings were good. A quality dividend is coming in May. Don't let the shorts scare you
    out of this company.
  • http://www.businesswire.com/news/home/20170509005390/en/Innovus-Pharma-Announces-Commercial-Partnership-Launch-FlutiCare%E2%84%A2

    Innovus Pharma Announces Commercial Partnership to Launch FlutiCare™ Under FDA Approved ANDA No. 207957
    Innovus Pharmaceuticals, Inc. (the “Company” or “Innovus Pharma”) (OTCQB Venture Market: INNV) and its partner West-Ward Pharm
    www.businesswire.com
  • GSK has 4 PDUFA dates upcoming before end of the year, plus 2 Phase III data, and 2 Phase II, data. If you are serious about keeping up with Biotech catalyst you might want to bookmark this site. Just type in your ticker symbol and get upcoming catalyst for any biotech you follow.
    http://biopharmcatalyst.com/calendars/fda-calendar

  • I had a situation where GSK could have traded with me a different Advair when my wife's dr switched her to a different formula. GSK sent a generic stock type refusal. I learned early in my sales career that "I you don't take care of your customers, someone else will." Well now I've sold my GSK (lack luster) stock and bought TEVA shares. Oh by the way TEVA is just coming out with products that have the same ingredients as advair (not a generic substitute, rather different concentrations of the active ingredients). Regards.
    Richard
  • GENERIC ADVAIR IS HERE!!!! HEARD IT WAS ABSOLUTELY TOP SECRET AT TEVA>>>WHICH MEANS THAT THE COMPLETE DUMB %$#@ ' S AT GSK HAD NO IDEA!!! BUY ALL THE TEVA YOU CAN!!!